Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genes altered in expression by Cisplatin treatment in lung cancer cell lines

ABSTRACT: Genes altered in expression by Cisplatin treatment in lung cancer cell lines

PROVIDER: PRJNA587480 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10398708_1.fastq.gz	Fastqsanger.gz
	SRR10398708_2.fastq.gz	Fastqsanger.gz
	SRR10398709_1.fastq.gz	Fastqsanger.gz
	SRR10398709_2.fastq.gz	Fastqsanger.gz
	SRR10398710_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

Genes altered in expression by Cisplatin treatment in lung cancer cell lines

Project description:Genes altered by Cisplatin treatment and long term-cultured in lung cancer cell lines

2019-11-05 | GSE139887 | GEO

Pulsed cisplatin treatment of A549 lung adenocarcinoma cells

Project description:A549 lung adenocarcinoma cells were pulsed for 2h with cisplatin and allowed to recover for 3 days. Cells were then FACS sorted based on size and enriched populations analysed for RNAseq.

2021-05-18 | GSE161800 | GEO

Noncoding RNA expression profiling of cisplatin-resistant cells derived from the A549 lung cell line (miRNA)

Project description:To determine the signaling networks that are dysregulated in cisplatin-resistant non-small cell lung cancer, noncoding RNA expression data were obtained from, and compared between, the lung adenocarcinoma cell line, A549, and its cisplatin-resistant derivative, A549/CDDP. Noncoding RNA expression data from a cisplatin-sensitive lung adenocarcinoma cancer cell line (A549) were collected and compared to noncoding RNA expression data from a cisplatin-resistant cell line (A549/CDDP). 3 independent experiments were completed for both the sensitive and resistant cell lines.

2013-01-15 | E-GEOD-43249 | biostudies-arrayexpress

Pulsed cisplatin treatment of A549 lung adenocarcinoma cells

Project description:Pulsed cisplatin treatment of A549 lung adenocarcinoma cells

| PRJNA679554 | ENA

Noncoding RNA expression profiling of cisplatin-resistant cells derived from the A549 lung cell line (lncRNA and mRNA)

2013-01-15 | E-GEOD-43493 | biostudies-arrayexpress

Bulk-ATAC sequencing in RUNX-altered murine lung adenocarcinoma cell lines

Project description:Bulk-ATAC sequencing in RUNX-altered murine lung adenocarcinoma cell lines

| PRJNA635682 | ENA

Expression and metylation data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines

Project description:This SuperSeries is composed of the following subset Series: GSE15372: Expression data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines. GSE15373: Promoter CpG island methylation data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines. Refer to individual Series

2009-04-17 | E-GEOD-15709 | biostudies-arrayexpress

Expression data from cultured human ovarian carcinoma cell lines with and without Cisplatin treatment

Project description:Chemo-resistance to platinum such as cisplatin is critical in the treatment of ovarian cancer. Recent evidences have linked epithelial-mesenchymal transition (EMT) with the drug resistance as a contributing mechanism. The current study explored the connection between cellular responses to cisplatin with EMT in ovarian cancer. 46 ovarian carcinoma cell lines expression data with and without Cisplatin treatment.

2014-07-29 | E-GEOD-47856 | biostudies-arrayexpress

Methylation profiling of cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines

Project description:Analysis of differences in DNA methylation in cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.

2008-01-11 | E-TABM-210 | biostudies-arrayexpress

RNAseq of two mouse lung cancer cell lines in a DSTYK-altered context

Project description:We report RNAseq data from two independent mouse syngeneic lung cancer cell lines LLC and UN-SCC679 in an altered DSTYK context Lung cancer remains the leading cause of cancer-related death worldwide. We identify DSTYK, a dual serine/threonine and tyrosine non-receptor protein kinase, as a novel actionable target altered in non-small cell lung cancer (NSCLC). We also show DSTYK´s association with a lower overall survival (OS) and poorer progression-free survival (PFS) in multiple patient cohorts. To ascertain the potential molecular carcinogenesis processes in which DSTYK was involved, we performed an RNAseq analysis of two different lung cancer cell lines with either overexpressed or inhibited DSTYK. Inhibition was achieved through shRNA technology. These cell lines were cultured in RPMI 1640 supplemented with 10% Fetalclone (Thermo Fisher Scientific) and 100 U/mL penicillin-100 µg/mL streptomycin (Thermo Fisher Scientific). All cells were grown in a humidified incubator containing 5% CO2 at 37°C. Cell lines were routinely tested for mycoplasma.

2022-09-23 | GSE212858 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data